Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Integra Lifesciences Holdings (IART) Asset Writedowns and Impairment (2017 - 2025)

Integra Lifesciences Holdings' Asset Writedowns and Impairment history spans 9 years, with the latest figure at $511.4 million for Q2 2025.

  • For Q2 2025, Asset Writedowns and Impairment rose 10038.08% year-over-year to $511.4 million; the TTM value through Dec 2025 reached $511.4 million, up 4088.43%, while the annual FY2025 figure was $511.4 million, 4088.43% up from the prior year.
  • Asset Writedowns and Impairment for Q2 2025 was $511.4 million at Integra Lifesciences Holdings, up from $36000.0 in the prior quarter.
  • Across five years, Asset Writedowns and Impairment topped out at $511.4 million in Q2 2025 and bottomed at $29000.0 in Q3 2024.
  • The 3-year median for Asset Writedowns and Impairment is $3.9 million (2021), against an average of $87.7 million.
  • The largest YoY upside for Asset Writedowns and Impairment was 10038.08% in 2025 against a maximum downside of 10038.08% in 2025.
  • A 3-year view of Asset Writedowns and Impairment shows it stood at $2.8 million in 2021, then tumbled by 98.69% to $36000.0 in 2024, then soared by 1420358.33% to $511.4 million in 2025.
  • Per Business Quant, the three most recent readings for IART's Asset Writedowns and Impairment are $511.4 million (Q2 2025), $36000.0 (Q4 2024), and $29000.0 (Q3 2024).